Investigate the therapeutic potential and metabolic mechanisms of the selective SGLT2 inhibitor ipragliflozin in a murine model of nonalcoholic steatohepatitis.
Evaluated the effect of the selective SGLT2 inhibitor ipragliflozin in NASH-model mice.
Ipragliflozin significantly improved the pathogenesis of NASH in mouse models.
Treatment reduced insulin resistance and attenuated hepatic lipotoxicity, indicating therapeutic efficacy in NASH accompanied by type 2 diabetes mellitus.
Abstract
Ipragliflozin improved the pathogenesis of NASH by reducing insulin resistance and lipotoxicity in NASH-model mice. Our results suggest that ipragliflozin has a therapeutic effect on NASH with T2DM.